Olaf van Tellingen
Overview
Explore the profile of Olaf van Tellingen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
3944
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ntafoulis I, Koolen S, van Tellingen O, den Hollander C, Sabel-Goedknegt H, Dijkhuizen S, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770529
Background: Glioblastoma is an aggressive and incurable type of brain cancer. Little progress has been made in the development of effective new therapies in the past decades. The blood-brain barrier...
2.
Champagne J, Nielsen M, Feng X, Montenegro Navarro J, Pataskar A, Voogd R, et al.
Immunity
. 2025 Jan;
58(1):247-262.e9.
PMID: 39755122
Prolonged exposure to interferon-gamma (IFNγ) and the associated increased expression of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) create an intracellular shortage of tryptophan in the cancer cells, which stimulates ribosomal...
3.
Jochems F, Baltira C, MacDonald J, Daniels V, Mathur A, de Gooijer M, et al.
Cell Death Differ
. 2024 Dec;
PMID: 39706991
Cellular senescence is a stress response that cells can employ to resist cell death. Senescent cells rely on anti-apoptotic signaling for their survival, which can be targeted by senolytic agents,...
4.
Verbeek T, Vrenken K, Arentsen-Peters S, Castro P, van de Ven M, van Tellingen O, et al.
Commun Biol
. 2024 Oct;
7(1):1257.
PMID: 39362994
KMT2A-rearranged acute lymphoblastic leukemia (ALL) is characterized by deregulation of the epigenome and shows susceptibility towards histone deacetylase (HDAC) inhibition. Most broad-spectrum HDAC inhibitors simultaneously target multiple human HDAC isoforms....
5.
Lentzas A, Venekamp N, Beijnen J, van Tellingen O
J Chromatogr B Analyt Technol Biomed Life Sci
. 2024 Sep;
1247:124308.
PMID: 39288576
A selective and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantitation of a cassette of 8 drugs, including docetaxel, erlotinib, loperamide,...
6.
Lentzas A, de Gooijer M, Zuidema S, Meurs A, Citirikkaya C, Venekamp N, et al.
Fluids Barriers CNS
. 2024 Aug;
21(1):62.
PMID: 39103921
Background: Pharmacotherapy for brain diseases is severely compromised by the blood-brain barrier (BBB). ABCB1 and ABCG2 are drug transporters that restrict drug entry into the brain and their inhibition can...
7.
Baltira C, Aronica E, Elmquist W, Langer O, Loscher W, Sarkaria J, et al.
Cell Rep Med
. 2024 Jun;
5(6):101609.
PMID: 38897176
ATP-binding cassette (ABC) transporters facilitate the movement of diverse molecules across cellular membranes, including those within the CNS. While most extensively studied in microvascular endothelial cells forming the blood-brain barrier...
8.
Qiao X, van der Zanden S, Li X, Tan M, Zhang Y, Song J, et al.
Mol Cancer
. 2024 Jun;
23(1):120.
PMID: 38831402
The efficacy of anthracycline-based chemotherapeutics, which include doxorubicin and its structural relatives daunorubicin and idarubicin, remains almost unmatched in oncology, despite a side effect profile including cumulative dose-dependent cardiotoxicity, therapy-related...
9.
Li W, Sparidans R, Wang Y, F Martins M, de Waart D, van Tellingen O, et al.
Biomed Pharmacother
. 2024 May;
175:116644.
PMID: 38692057
Transmembrane drug transporters can be important determinants of the pharmacokinetics, efficacy, and safety profiles of drugs. To investigate the potential cooperative and/or counteracting interplay of OATP1A/1B/2B1 uptake transporters and ABCB1...
10.
Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, et al.
Cell Rep Med
. 2024 Mar;
5(3):101471.
PMID: 38508142
Drug-tolerant persisters (DTPs) are a rare subpopulation of cells within a tumor that can survive therapy through nongenetic adaptive mechanisms to develop relapse and repopulate the tumor following drug withdrawal....